We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 14, 2020

Vocimagene Amiretrorepvec Plus Flucytosine vs Standard of Care Following Tumor Resection in Patients With Recurrent High-Grade Glioma

JAMA Oncology

 

Additional Info

JAMA Oncology
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial
JAMA Oncol 2020 Oct 29;[EPub Ahead of Print], TF Cloughesy, K Petrecca, T Walbert, N Butowski, M Salacz, J Perry, D Damek, D Bota, C Bettegowda, JJ Zhu, F Iwamoto, D Placantonakis, L Kim, B Elder, G Kaptain, D Cachia, Y Moshel, S Brem, D Piccioni, J Landolfi, CC Chen, H Gruber, A Rao, D Hogan, W Accomando, D Ostertag, TT Montellano, T Kheoh, F Kabbinavar, MA Vogelbaum

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading